-
FXR Phase Separation Clusters Coronavirus Organelles
2026-09-21
Li et al. identify fragile X–related proteins as host factors that organize β-coronavirus double-membrane vesicles through liquid–liquid phase separation. The study links FXR condensates to replication-organelle clustering, local translation, and SARS-CoV-2 replication, while offering a framework for interpreting fluorescence and ultrastructural imaging data.
-
CDK4/6 and BET Inhibitors Restrain PDAC EMT
2026-09-21
Gu et al. show that palbociclib can suppress pancreatic ductal adenocarcinoma cell proliferation while unexpectedly increasing migration, invasion, and epithelial-to-mesenchymal transition. Their study identifies BET inhibition with JQ1 as a complementary strategy that restores antitumor activity by restraining GSK3β-mediated Wnt/β-catenin signaling and its interaction with TGF-β/Smad pathways.
-
From Capped mRNA to Local Bladder Therapy
2026-09-20
Intravesical p21 mRNA–loaded lipid nanoparticles illustrate how localized delivery, tumor-suppressor replacement, and disciplined IVT process development can converge into a translational strategy for bladder cancer. This article interprets the mechanistic evidence, identifies development gates, and positions EZ Cap™ Reagent GG as a candidate component for a controlled mRNA manufacturing workflow.
-
CAY10499 in Lipid-Driven Translational Research
2026-09-19
CAY10499 provides a pharmacological route to dissect HSL, MGL, FAAH, and lipid-signaling biology alongside the EV-transferred ACLY mechanism that drives immunosuppressive macrophage differentiation in hepatocellular carcinoma.
-
IRF1–ox-mtDNA–NLRC5 Signaling in Lung IRI
2026-09-19
This study identifies an ex-His–mitochondria–IRF1–NLRC5 pathway that connects extracellular histones with oxidized mitochondrial DNA release and macrophage PANoptosis during lung ischemia–reperfusion injury. Its integration of mouse, alveolar macrophage, and transplant-recipient analyses provides a mechanistic framework for primary graft dysfunction and highlights measurable signaling nodes for future intervention studies.
-
FPR2/ALX, Microglia, and NK Cells in Astrocytopathy
2026-09-18
The reference study identifies FPR2/ALX stimulation with Quin-C1 as a way to limit AQP4-IgG- and complement-associated autoimmune astrocytopathy in mice. Its depletion and pathway-inhibition experiments connect the protective phenotype to microglia, natural killer cells, and SYK-AKT signaling, while also defining important translational limitations.
-
Z-VAD-FMK: Mechanism, Evidence, and Workflow
2026-09-18
Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor used for apoptosis inhibition and apoptotic pathway research. It helps distinguish caspase-dependent apoptosis from ferroptosis, but it should not be interpreted as a universal blocker of regulated cell death.
-
HyperFluor 488 Goat Anti-Rabbit IgG Guide
2026-09-17
HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody is a fluorescent antibody conjugate for detecting rabbit primary antibodies in immunofluorescence, immunocytochemistry, flow cytometry, and fluorescence microscopy. It should be used only when the primary antibody is rabbit-derived and the detection system is compatible with the HyperFluor 488 signal, not as a substitute for nonfluorescent detection or a reagent for non-rabbit primaries.
-
HyperFluor™ 488: Assay Design for FXR Imaging
2026-09-17
HyperFluor™ 488 Rabbit Anti-Goat IgG (H+L) Antibody supports sensitive detection of goat primary antibodies across imaging, blotting, and cytometry. This article presents a mechanism-to-measurement framework for distinguishing coronavirus replication-organelle clustering from simple fluorescence colocalization.
-
CAY10499 for Dissecting Lipid-Driven TAM Biology
2026-09-16
CAY10499 is an inhibitor of human hormone sensitive lipase and monoglyceride lipase that can help separate lipid hydrolysis from EV-transferred ACLY signaling in tumor-associated macrophage models. This article develops a causal assay framework linking lipase activity, 2-AG metabolism, fatty-acid mobilization, and HCC immunometabolism.
-
Cyclo (-RGDfC) for 96-Well Integrin Assays
2026-09-15
Cyclo (-RGDfC) combines cyclic RGD recognition of integrin αvβ3 with a practical DMSO-based workflow for adhesion, migration, angiogenesis, and tumor-targeting studies. Paired with an open-platform 96-well digital light printer, it supports a differentiated path from uniform peptide dosing to spatially patterned hydrogel assays, while keeping peptide handling and plate variability under control.
-
Affordable GRO-seq for Nascent RNA in Bread Wheat
2026-09-15
The reference protocol redesigns Global Run-On sequencing (GRO-seq) for complex plant genomes by adding rRNA depletion after nuclear RNA isolation and before nascent RNA immunoprecipitation. In bread wheat, this placement increased the reported proportion of valid sequencing data 20-fold, improving the practicality of enhancer-transcription profiling without changing the core BrUTP-based assay principle.
-
Triacetin: From Acetate Donor to Assay Insight
2026-09-14
Triacetin, or glyceryl triacetate, is more than a formulation excipient: it is an acetate-bearing perturbagen that can connect metabolic, epigenetic, and cancer assays. This evidence-led guide explains how to interpret its biology, select experimental contexts, and avoid confusing solvent effects with mechanism.
-
Cholecystokinin Octapeptide Ammonium Workflow
2026-09-14
Build more informative CCK assays by pairing CCK-8 ammonium exposure with receptor controls, secreted-factor measurements, and pathway-resolved readouts. This guide translates the atrial ANP study into practical workflows while addressing peptide handling, concentration selection, and cross-model interpretation.
-
EV-ACLY Drives TAM Differentiation in HCC
2026-09-13
The reference study identifies extracellular vesicle-delivered ATP-citrate lyase as a metabolic signal that converts monocytes into immunosuppressive tumor-associated macrophages in hepatocellular carcinoma. By engineering CD81-decorated liposomal vesicles to deliver ACLY or its inhibitor, the authors connect palmitate-dependent protein S-palmitoylation with tumor progression and improved anti-PD-1/PD-L1 responses.